A Randomized, Open-Label, Neoadjuvant Prostate Cancer Trial of Abiraterone Acetate Plus LHRHa Versus LHRHa Alone.

Trial Profile

A Randomized, Open-Label, Neoadjuvant Prostate Cancer Trial of Abiraterone Acetate Plus LHRHa Versus LHRHa Alone.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2014

At a glance

  • Drugs Abiraterone acetate (Primary) ; Leuprorelin; Prednisone
  • Indications Prostate cancer
  • Focus Biomarker; Therapeutic Use
  • Sponsors Cougar Biotechnology
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Mar 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Dec 2012 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top